Bust #1: The Singing Diabetes Ad, Slowed Way Down

🎬 Bust #1 · The Commercial As You See It

Everybody Is Singing. Everybody Is Dancing. Nobody Is Reading.

Welcome to COMMERCIAL BUSTERS BY AOP3D — the blog where we do the one thing commercials pray you never do: we pause, we rewind, and we read the tiny words at the bottom.

Our first bust is the most famous prescription-drug musical on TV: the once-weekly Ozempic® (semaglutide) commercial. You know the one. Happy people, sunshine, a catchy jingle you will be humming in the shower — “Oh, oh, oh…” — and the warm feeling that this little pen has basically solved life.

Then, while everyone is still dancing, a voice shows up talking like an auctioneer who double-fisted espresso. In about the time it takes to sneeze, it races through tumors, pancreatitis, allergic reactions, and kidney problems — and the song just keeps smiling through all of it.

To be fair — and we are always fair here — the warnings ARE in the commercial. The law requires them. They are just delivered at highway speed, in tiny type, while a jingle is doing a tap dance on your attention. So today, we slow the whole thing waaay down.

🔍 The Fine Print, Slowed Waaay Down

What That Fast Voice Is Actually Saying

Here is the fast part, translated into normal human English, based on the FDA-approved labeling for this medicine:

• “It caused thyroid tumors in animal studies.” The label carries the FDA’s strongest kind of warning — a boxed warning. In studies, semaglutide caused thyroid C-cell tumors in rodents. Whether it causes them in people is unknown. That is why the label says people with a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma, or a condition called MEN 2, should not use it.
• “Serious side effects may include pancreatitis.” That means inflammation of the pancreas. The labeling tells patients to watch for severe stomach pain that may spread to the back, and to get medical help promptly if it happens.
• “Tell your doctor about vision changes.” The label warns about complications of diabetic retinopathy — an eye condition linked to diabetes — and says to report vision changes.
• “It may increase the risk of low blood sugar…” Especially when used together with insulin or a type of diabetes pill called a sulfonylurea. Two blood-sugar-lowering medicines together can push blood sugar too low.
• “Never share your pen.” Even if the needle is changed. Sharing an injection pen can spread serious infections.
• “Common side effects are nausea, vomiting, diarrhea, stomach pain, and constipation.” Notice the commercial lists these in one cheerful breath. The labeling adds the part the jingle leaves out: vomiting and diarrhea can cause dehydration, and dehydration can make kidney problems worse. The label also lists warnings for severe allergic reactions and gallbladder problems.

None of that means the medicine is “bad.” It means it is a real prescription medicine with real benefits for the right patients and real risks that deserve more than a 12-second speed-read.

🧠 What The Song Doesn’t Spell Out

The Three Things The Dancing Doesn’t Tell You

1. What it is actually approved for. Under the Ozempic brand name, this medicine is FDA-approved to help adults with type 2 diabetes improve their blood sugar (along with diet and exercise), and to lower the risk of major cardiovascular events in certain adults with type 2 diabetes and known heart disease. It is not approved for type 1 diabetes — and, brand-name detail almost everybody misses, Ozempic itself is not FDA-approved as a weight-loss drug, even though weight loss was seen in its studies and even though a different brand name for the same active ingredient is marketed for weight management.

2. What those happy numbers really mean. When the ad says many adults in a study reached an A1C under 7% and lost up to about 12 pounds on average, those are study results, in study populations, under study conditions. “A majority” is not “everybody,” “on average” is not “you will,” and “may lose weight” is doing a lot of quiet work in that sentence.

3. What it costs you. Commercials almost never talk price, coverage, prior authorizations, or what happens if your insurance says no. The ad sells the feeling. The pharmacy counter delivers the math. Those are two very different conversations — and only one of them is sung.

⚖️ The Busters Verdict

Verdict: The Truth Was There — It Was Just Doing 90 MPH

This commercial does not hide its warnings in a vault. It does something sneakier and completely legal: it puts the happiest music in the world in front, and the hardest information in the back, read at auctioneer speed in print sized for an ant with a library card.

So here is your Commercial Busters homework — the questions worth taking to a doctor or pharmacist, because they are the professionals and we are not:

• “Am I actually in the group this medicine was studied and approved for?”
• “Do any of those boxed-warning conditions run in my family?”
• “What do I do — exactly — if I get severe stomach pain or vision changes?”
• “How do my other medicines change the low-blood-sugar risk?”
• “What will this actually cost me every month, with my coverage?”

Tomorrow, another commercial gets busted. A drug, a “free” phone, an insurance promise, a miracle gadget — nobody’s fine print is safe. If it talks fast and prints small, it belongs here.

Sources you can check yourself: the FDA’s Ozempic labeling summary in its September 9, 2025 letter to Novo Nordisk (fda.gov) and the FDA-approved DailyMed drug label for Ozempic (semaglutide), which lists the boxed warning, warnings and precautions, and common adverse reactions quoted in plain English above.

Final reminder: This post is for educational and entertainment purposes only. It is not medical, financial, legal, insurance, or any other professional advice, and it should not be used to make any kind of decision. Talk to a qualified professional about your own situation. Please do not contact us about the products, drugs, policies, or services covered here — we do not provide advice on any of them.